Weigao Medical Polymer Calls 2026 EGM to Approve Key Transaction and Non-Competition Agreements

Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) has shared an announcement.

Shandong Weigao Group Medical Polymer Company Limited has convened its first extraordinary general meeting of 2026 for 12 February in Weihai, Shandong, seeking shareholder approval for a series of transaction documents, including a sale and purchase agreement, a compensation agreement and a letter of non-competition undertakings. The board is asking shareholders to ratify these agreements and to authorise any director to execute all necessary actions and documentation, a move that, once approved, will formalise the contemplated transactions and potentially reshape parts of the group’s structure and competitive arrangements within the wider Weigao ecosystem.

The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

More about Shandong Weigao Group Medical Polymer Co

Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated medical device manufacturer specialising in medical polymer products. Listed in Hong Kong, the company focuses on supplying a broad range of disposable medical consumables and related products to hospitals and healthcare institutions, with a significant presence in the Chinese healthcare market.

YTD Price Performance: 2.19%

Average Trading Volume: 14,697,933

Technical Sentiment Signal: Sell

Current Market Cap: HK$23.2B

For detailed information about 1066 stock, go to TipRanks’ Stock Analysis page.